Missed the digital ILC 2020? Here’s a look back at the highlights
The main theme this year was a focus on the kinds of everyday life changes that can help or even reverse liver disease. Sharing epidemiological and real-world data on the latest liver research, this year’s expert-led sessions included:
- Updates on non-alcoholic fatty liver disease, from pathophysiology to drug targets, as well as a discussion on the challenges and progress in NASH drug development.
- An advanced cirrhosis symposium covering topics such as gut microbiota in chronic liver disease and long-term albumin treatment in decompensated cirrhosis.
- Talks by world-leading experts on the potential of multi-omics technologies and artificial intelligence in conditions such alcoholic liver disease, liver fibrosis and liver cancer.
This year’s conference was packed with a wide range of interactive and engaging content that shared recent data, presented studies and discussed the hottest topics in liver disease. If you want to see more, click here to view the full scientific programme from the digital ILC 2020.
Related news and insights
Intercept Pharmaceuticals, Inc. announced an update on the timing of its pre-submission meeting with the FDA regarding the potential resubmission of its nonalcoholic steatohepatitis (NASH) New Drug Application (NDA) based on an interim analysis of the REGENERATE trial in patients with fibrosis due to NASH.